新天药业：欣力康胶囊获药物临床试验批准

Core Viewpoint - The company Xin Tian Pharmaceutical has received approval from the National Medical Products Administration to conduct clinical trials for its Xin Likang capsules, aimed at treating cancer-related fatigue, marking a significant step in addressing an unmet medical need in this area [1] Company Summary - Xin Tian Pharmaceutical announced the receipt of a clinical trial approval notice for Xin Likang capsules, which are a unique Miao medicine [1] - The clinical trials will focus on validating the efficacy of Xin Likang capsules in treating cancer-related fatigue specifically in colon cancer patients [1] - Currently, there are no drugs available in the domestic or international markets for the treatment of cancer-related fatigue [1] Industry Summary - The approval for clinical trials highlights a potential breakthrough in the pharmaceutical industry, particularly in the niche of cancer-related fatigue treatment [1] - The development of Xin Likang capsules could fill a significant gap in the market, as there are no existing therapies for this condition [1] - The progress and results of the clinical trials remain uncertain, and the company will fulfill its information disclosure obligations as required [1]